^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

BCMA-BCL2L1-CART

i
Other names: BCMA-BCL2L1-CART, BCL2L1 armoured BCMA targeting CAR T
Associations
Trials
Company:
University of Calgary
Drug class:
BCMA-targeted CAR-T immunotherapy
Related drugs:
Associations
Trials
1year
Bclxl Prevents Progressive Exhaustion in BCMA CAR T Cells with Maintenance of High TCF1 Expressing T Cells (ASH 2023)
Furthermore, CITEseq profiling on harvested human T cells 7 days post CAR T cells infusion to diseased mice revealed a differential T cell repertoires and phenotypes between BCMA_CAR and BCMA_BCL2L1 CARs...In summary, we have identified a role for BCLxL and two mutant variants lacking a loop regulatory domain (BCLxLΔ26-83 or BCLxLΔ46-83), in maintenance of BCMA CAR T cells in central memory and precursor exhausted states with retained high TCF1 expression, even under hypoxic and chronic antigenic stimulation conditions. These studies further support the clinical development of a BCL2L1 armored CAR T cells for the treatment of MM.
Clinical • CAR T-Cell Therapy • IO biomarker
|
CD8 (cluster of differentiation 8) • BCL2L1 (BCL2-like 1) • CD4 (CD4 Molecule)
|
BCL2L1 overexpression
|
BCMA-BCL2L1-CART
3years
A BCL2L1 Armoured BCMA Targeting CAR T Cell to Overcome Exhaustion and Enhance Persistence in Multiple Myeloma (ASH 2021)
Our studies indicate that BCL2L1 blockade of AICD not only enhanced the viability and proliferation of BCMA targeting CAR T cells but surprisingly also reduced their functional exhaustion. Our findings provide an novel approach for CAR T optimization and overcoming disease relapse resulting from lack of persistence and/or T cells exhaustion.
CAR T-Cell Therapy • PD(L)-1 Biomarker • IO biomarker
|
LAG3 (Lymphocyte Activating 3) • BCL2L1 (BCL2-like 1) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • FASLG (Fas ligand) • CCR7 (Chemokine (C-C motif) receptor 7) • FAS (Fas cell surface death receptor) • B3GAT1 (Beta-1,3-Glucuronyltransferase 1)
|
PD-1 expression
|
BCMA-BCL2L1-CART